Jefferies Financial Group Reaffirms Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by Jefferies Financial Group in a research report issued on Tuesday, October 20th, Digital Look reports. They presently have a £175 price objective on the biopharmaceutical company’s stock. Jefferies Financial Group‘s target price indicates a potential upside of 35.89% from the company’s previous close.

A number of other research analysts have also recently issued reports on the stock. Citigroup boosted their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada reissued an “outperform” rating and issued a £145 price target on shares of AstraZeneca in a report on Tuesday, September 8th. Berenberg Bank restated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a research report on Wednesday, October 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £117 price target on shares of AstraZeneca in a research report on Tuesday, September 29th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded up GBX 24 during midday trading on Tuesday, hitting £128.78. 21,074,045 shares of the company were exchanged, compared to its average volume of 30,006,750. AstraZeneca has a 52 week low of £114.04 and a 52 week high of £157.32. The firm has a 50 day simple moving average of £121.76 and a 200-day simple moving average of £134.56. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a market cap of £199.73 billion, a P/E ratio of 19.28, a PEG ratio of 0.86 and a beta of 0.21.

Insider Transactions at AstraZeneca

In related news, insider Michel Demare acquired 2,500 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were bought at an average price of £121.21 per share, with a total value of £303,025. Insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.